Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Hunt for Reliable Biomarkers for Immunotherapy Continues in Melanoma

Although immune checkpoint inhibitors have revolutionized the treatment of patients with melanoma, identifying reliable biomarkers of response to this approach has proven to be exceedingly challenging, according to Douglas B. Johnson, MD, MSCI.

Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model

Since patients with stage I/IIA cutaneous melanoma (CM) are currently not eligible for adjuvant therapies despite relapse risk uncertainty, researchers examined the ability of a recently developed model that combines clinicopathologic and gene expression variables (CP-GEP) to identify patients with stage I/IIA melanoma who have a high risk for disease relapse.

Medicare Administrative Contractor CGS Aligns Coverage for Melanoma Risk Stratification Tests

Medicare Administrative Contractor CGS Administrators has aligned its coverage for melanoma risk stratification tests in patients with cutaneous melanoma, including Castle Biosciences’ DecisionDx-Melanoma test.

Posted in Melanoma News, Patients, Latest News

26th November 2020 – MRV Scientific Exchange, Public Forum

6:00 – 8:30pm 26th November 2020 MRV Scientific Exchange, Public Forum Register via link: https://unimelb.zoom.us/webinar/register/WN_ZtbIh9u1QhyOqlOGDNq1WQ

Posted in MRV Events, Events